The ATS encourages Non-CME Symposia in conjunction with the International Conference. All full-conference participants are encouraged to attend these programs.
This program will explore how the physiological finding of “airflow obstruction” became central to the definition, classification, and treatment of COPD, even though this occurs late in the disease process. Rethinking how we approach disease modification in the future will require that we rethink what comprises early disease, before obstruction is present, and focus on important phenotypes, endotypes, and treatable traits that will guide interventions.

**Bart Celli, MD  Moderator**
Professor of Medicine, Harvard Medical School

**Brad Drummond, MD, MHS**
Associate Professor of Medicine, University of North Carolina School of Medicine
Director, Obstructive Lung Diseases Clinical and Translational Research Center

**MeiLan K Han, MD**
Professor, Division of Pulmonary and Critical Care, University of Michigan

**Dave Mannino, MD, FCCP**
US Medical Expert, GSK

**Sunday, May 19**
11:30am-12:15pm
Theater 2

---

This symposium will provide an in-depth discussion around the data on IgE levels, exhaled nitric oxide, and circulating eosinophil counts in severe asthma. The role of these measurements as biomarkers for predicting exacerbations, evaluating disease control, and determining response to biologic therapies will be reviewed.

**Eugene Bleecker, MD**
Professor of Medicine, The University of Arizona Health Sciences
Co-Chief, Division of Genetics, Genomics, and Precision Medicine,
UA Department of Medicine; Co-Director, Division of Pharmacogenomics,
UA Center for Applied Genetics and Genomic Medicine

**Geoffrey Chupp, MD**
Professor of Medicine
Director, Yale Center for Asthma and Airways Disease
Director, Pulmonary Function Laboratory, Yale New Haven Hospital

**Tuesday, May 21**
1:15pm-2:00pm
Theater 2

---

An Industry Theater Presentation at the ATS 2019 International Conference
This presentation is sponsored by GSK, and is open to all ATS 2019 International Conference attendees.

Trademarks are owned by or licensed to the GSK group of companies.

©2019 GSK group of companies or its licensor.
February 2019. Produced in USA.
Event listings current as of March 25, 2019

ATS 2019  
NON-CME SYMPOSIA LOCATOR GUIDE

See the ATS Final Program and the Exhibit & Innovation Guide for a complete list and map of ATS 2019 hotels.
The Current State of Idiopathic Pulmonary Fibrosis

An Industry-Organized Symposium at the ATS 2019 International Conference

This symposium will enlist two expert pulmonologists presenting information on idiopathic pulmonary fibrosis (IPF). Current knowledge regarding IPF, including the updated 2018 ATS/ERS/JRS/ALAT diagnostic guidelines, as well as recommendations for use of multidisciplinary discussions in patient diagnosis, will be reviewed.

May 21, 2019
6:30 PM
Dinner/Symposium
Fairmont Dallas
Regency Ballroom

This presentation is sponsored by and made on behalf of Boehringer Ingelheim Pharmaceuticals, Inc. Presentation content has been reviewed for consistency with FDA guidelines and is not approved for continuing medical education credit. Speakers receive fair market value compensation for this presentation. Aspects of this program may be reportable under the Physicians Payment Sunshine Act. Pursuant to the PhRMA (Pharmaceutical Research and Manufacturers of America) Code on Interactions with Healthcare Professionals, attendance at this promotional program is limited to healthcare professionals, attendance by healthcare professionals’ spouses or guests is not permitted.

Boehringer Ingelheim

Copyright © 2019, Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved (03/19) EM-US-100889
**Sunday, May 19**

6:30-9:30 p.m.

**A Disease-State Presentation: Exploring Eosinophilic Granulomatosis With Polyangiitis (EGPA)**

**Hyatt Regency Dallas, Landmark Ballroom C**

Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare vasculitis that often involves the respiratory tract, affects small-to-medium vessels, and is associated with asthma and eosinophilia. EGPA is difficult to diagnose and manage due to its rarity and complexity. Early recognition is critical to avoid organ damage. This educational session will review the pathogenesis, clinical manifestations, classification criteria, diagnosis, and prognosis of EGPA.

**Speaker:** Michael Wechsler, MD, MMSc, professor of medicine, director of the asthma program at National Jewish Health, director of the Cohen Family NJH Asthma Institute, division of pulmonary, critical care and sleep medicine in the department of medicine at National Jewish Health and University of Colorado School of Medicine

**Company:** GlaxoSmithKline

6:30-9:30 p.m.

**A Multidisciplinary Case Study Approach: From Recognition to Progression of Fibrosing ILDs**

**Sheraton Dallas Hotel, Lone Star Ballroom A2-A4**

This symposium will enlist an expert multidisciplinary panel detailing various clinical presentations of progressive fibrosing interstitial lung diseases. Case studies will be used and will focus on initial clinical presentations of various fibrotic ILDs, disease progression over time, and how identifying the progressive phenotype of ILD-associated diseases will help guide patient care decisions. This interactive panel discussion will demonstrate the importance of multidisciplinary discussions in resolving diagnostic challenges.

**Speakers:** Gregory P. Cosgrove, MD, FCCP, assistant director of the interstitial lung disease program, endowed chair in interstitial lung disease at National Jewish Health; Flavia V. Castelino, MD, director of the scleroderma program, assistant professor of medicine at Massachusetts General Hospital, Harvard Medical School; Lida Hanri, MD, PhD, assistant pathologist, assistant professor of pathology at Massachusetts General Hospital, Harvard Medical School; Geoffrey Chupp, MD, director at the Yale Center for Asthma and Airway Disease; Laren Tan, MD, assistant professor of internal medicine at Loma Linda University Medical Center

**Company:** Sanofi Genzyme and Regeneron

6:30-9:30 p.m.

**Bronchiectasis: Emerging Trends and Unmet Needs**

**Fairmont Dallas, Regency Ballroom**

Emerging evidence shows that non-cystic fibrosis bronchiectasis (NCFB) is more common than previously thought and is viewed as a severe comorbidity of COPD. Appropriate diagnosis and treatment are key to improving outcomes and quality of life, and to helping reduce health care costs. In this non-CME educational symposium, global NCFB experts describe why awareness of the condition is growing, how to accurately identify patients with NCFB, and how to address symptoms within the framework of “treatable traits.” They will present the latest research, clinical guidelines, and actionable information related to this under-recognized but critically important pulmonary condition.

**Speakers:** Michael Polkey, MD, Royal Brompton Hospital in London, U.K.; Timothy Aksamit, MD, Mayo Clinic in Massachusetts General Hospital, Harvard Medical School; Geoffrey D. Rubin, MD, MBA, FACR, George G. Gellar Distinguished Professor of Radiology at Duke University School of Medicine

**Company:** Boehringer Ingelheim Pharmaceuticals, Inc.
Early Diagnosis and Augmentation for

ALPHA-1 ANTITRYPSIN DEFICIENCY LUNG DISEASE

TUESDAY, MAY 21, 2019
6:30 PM – Dinner
7:00 PM – Patient Panel Discussions

Hyatt Regency Dallas | Landmark Ballroom A

CLINICAL CASES IN AATD PRESENTED BY THE PANEL
✓ Patient 1 – Delayed Diagnosis
✓ Patient 2 – Interpreting Genetic Testing
✓ Patient 3 – Treatment Selection
✓ Audience-Submitted Patient Case Challenges

REGISTER TODAY! www.RMEI.com/AATD2019

THREE WORLD-RENOWNED EXPERTS and ONE LIVE PATIENT with AATD

Hear from these clinical experts and a real patient living with AATD during this dynamic series of panel discussions. Each panel addresses a different challenging case of a patient with AATD – such as high-risk genotype and low FEV₁ – as well as diagnostic considerations and therapeutic interventions, including augmentation therapy.

While registering, you are encouraged to
SUBMIT
your challenging AATD clinical cases for review and live discussion by the full faculty panel.

Supported by independent educational grants from CSL Behring, Grifols, and Shire, now part of Takeda.
THREE WORLD-RENOWNED EXPERTS and ONE LIVE PATIENT with AATD during this dynamic series of panel discussions. Each panel addresses risk genotype and low FEV – as well as diagnostic considerations and DEFICIENCY LUNG DISEASE.

Hear from these clinical experts and a real patient living with AATD – such as high-

REGISTER TODAY! www.RMEI.com/AATD2019

your challenging AATD clinical cases for review and live discussion by the
therapeutic interventions, including augmentation therapy.

ALPHA-1 ANTITRYPSIN

Hyatt Regency Dallas
| Landmark Ballroom A

Audience-Submitted Patient Case Challenges
√
√

CLINICAL CASES IN AATD PRESENTED BY THE PANEL

PhD, FCCP (Chair)
Sandhaus, MD, Robert A.

CSL Behring, Grifols, and Shire, now part of Takeda.

CLINICAL CASE

Stocks, MD, James M.

Perelman School of Medicine, University of Pennsylvania; Bruce K. Rubin, MD, MEng, MBA, FRCP, Jessie Ball duPont Distinguished Professor and chair in the department of pediatrics, professor of biomedical engineering, and physician in chief at Virginia Commonwealth University School of Medicine and Children’s Hospital of Richmond at VCU; Christopher Towe, MD, assistant professor of pediatrics, pediatric pulmonary and pediatric lung transplant and director of rare lung diseases at Cincinnati Children’s Hospital Medical Center

Company: Vindico Medical Education, supported by an educational grant from Guerbet, LLC

6:30-9:30 p.m.

Nasal High Flow in the Critical Care Setting
Hyatt Regency Dallas, Landmark Ballroom A

This session highlights advances in improved care of respiratory failure and the clinical outcomes in critical care and emergency medicine using nasal high flow therapy. Nasal high flow is optimal humidified respiratory support at up to 60 L/min with the AIRVO2 to provide reduction of dead space, delivery of a dynamic positive airway pressure, airway hydration, patient comfort, and supplemental oxygen. These mechanisms contribute to physiological effects such as reduced respiratory rate, improved oxygenation, reduced carbon dioxide levels, and improved mucus clearance. Clinical studies demonstrate that nasal high flow therapy may reduce escalation of care, reduce mortality rates, and improve symptomatic relief.

Speakers: Nicholas Hill, MD, professor at Tufts University; Gregory Schmidt, MD, professor at the University of Iowa; Tomaso Mauri, MD, PhD, associate professor at the University of Milan

Company: Fisher & Paykel Healthcare

6:30-9:30 p.m.

In Pursuit of the Leaking Lymph: Nonmalignant Thoracic Lymphatic Disorders
Sheraton Dallas Hotel, Lone Star Ballroom B

Experts will discuss classification of pulmonary lymphatic disorders and evaluate new imaging and therapeutic approaches for the differentiation and treatment of these disorders. They will also assess pulmonary involvement in patients with lymphatic malformations. Interactive clinical case presentations will provide scientific pearls for integrating diagnostic and therapeutic algorithms into your practice.

Speakers: Maxim Itkin, MD, FSIR, professor of radiology and pediatrics at the Center for Lymphatic Disorders at Perelman School of Medicine, University of Pennsylvania; Jennifer Ingraham, MD, medical director of rare lung diseases at Cincinnati Children’s Hospital Medical Center; Anais Elbarbary, MD, assistant professor of radiology at Northwestern University Feinberg School of Medicine

Company: RespirTech, a Philips Company

6:30-9:30 p.m.

Nasal High Flow in the Critical Care Setting
Hyatt Regency Dallas, Landmark Ballroom A

This session highlights advances in improved care of respiratory failure and the clinical outcomes in critical care and emergency medicine using nasal high flow therapy. Nasal high flow is optimal humidified respiratory support at up to 60 L/min with the AIRVO2 to provide reduction of dead space, delivery of a dynamic positive airway pressure, airway hydration, patient comfort, and supplemental oxygen. These mechanisms contribute to physiological effects such as reduced respiratory rate, improved oxygenation, reduced carbon dioxide levels, and improved mucus clearance. Clinical studies demonstrate that nasal high flow therapy may reduce escalation of care, reduce mortality rates, and improve symptomatic relief.

Speakers: Nicholas Hill, MD, professor at Tufts University; Gregory Schmidt, MD, professor at the University of Iowa; Tomaso Mauri, MD, PhD, associate professor at the University of Milan

Company: Fisher & Paykel Healthcare

6:30-9:30 p.m.

Systemic Sclerosis-Associated Interstitial Lung Disease: Expert Insights on Early Diagnosis and Optimal Management
Hyatt Regency Dallas, Marsealis Exhibit Hall A

Systemic sclerosis (SSc) is a rare, often fatal, connective tissue disease that affects multiple organ systems. Interstitial lung disease (ILD) occurs in the majority of patients with SSc and is now the No. 1 cause of death in these patients. Treatment for SSc-associated ILD has historically been limited; however, novel therapies have shown promise in clinical trials. Through a live, non-CME MasterClass...
held during the American Thoracic Society International Conference on May 19, 2019, in Dallas, Texas, a panel of expert faculty will offer insight to help clinicians achieve a greater understanding into the recognition, diagnosis, and management of SSc-ILD, including the latest clinical evidence with respect to emerging therapies.

**Speakers:** Marilyn K. Glassberg, MD, director, interstitial lung disease program director, pulmonary diseases at interdisciplinary stem cell institute, professor of medicine, surgery, and pediatrics vice chair of medicine for diversity and innovation at the University of Miami School of Medicine; Aryeh Fischer, MD, associate professor of medicine division of rheumatology, division of pulmonary sciences and critical care medicine at the University of Colorado School of Medicine; Kristin B. Highland, MD, MSCR, associate program director for research and scholarly activity, pulmonary fellowship at the Cleveland Clinic

**Company:** PVI, PeerView Institute for Medical Education, supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, A Member of the Roche Group

**Register:** PeerView.com/ILD19Dallas

---

**6:30-9:30 p.m.**

**Uncontrolled Obstructive Airway Diseases: Treatment and Stepwise Management Approaches to Severe Asthma and Exacerbations in Chronic Obstructive Pulmonary Disease (COPD)**

**Hyatt Regency Dallas, Landmark Ballroom B**

Learn treatment and early management approaches to severe asthma and exacerbations in COPD. A national panel of experts will discuss the burden and impact of severe asthma as well as the challenges associated with overreliance on oral corticosteroids (OCS). Also, the importance of COPD exacerbations and their impact on patients in real-world clinical practice will be discussed as well as the need to help prevent future exacerbations.

**Speakers:** Nicola Hanania, MD; Gene Bleeker, MD; Gary Ferguson, MD

**Company:** AstraZeneca

---

**TUESDAY**

**MAY 21**

**6:30 PM**

**IPF**

**Tips to Better Management**

**HYATT REGENCY**

PILOTforPulmonary.org/IPF19

**U.S. Presidents with Severe Asthma**

**FAIRMONT**

PILOTforPulmonary.org/asthma19
Tuesday, May 21

6:30-9:30 p.m.
Are We There Yet? Tips to Better IPF Management
Hyatt Regency Dallas, Marsalis Exhibit Hall A

Our faculty will engage learners in interactive “What would YOU do?” case-based questions and demonstrate the positive impact of shared decision-making. It will include a short patient testimonial as to the impact and burden that IPF has had on them and how shared decision-making made a positive difference in their care plan, treatment adherence, and quality of life.

Speakers: Marilyn K. Glassberg, MD, professor of medicine and surgery at the Miller School of Medicine at the University of Miami, Florida; Lisa H. Lancaster, MD, program medical director of the interstitial lung disease program at the Vanderbilt University Medical Center in Nashville, Tennessee; Fernando J. Martinez, MD, MS, chief of the division of pulmonary and critical care medicine at New York Presbyterian Hospital/Weill Cornell Medical Center in New York

Company: The France Foundation, supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, A Member of the Roche Group

Register: pilotforpulmonary.org/ipf19

6:30-9:30 p.m.
Early Diagnosis and Augmentation for Alpha-1 Antitrypsin Deficiency Lung Disease: A Care Team ForumSM
Hyatt Regency Dallas, Landmark Ballroom A

Learn what you’re missing about Alpha-1 antitrypsin deficiency (AATD) lung disease. Interact with world-renowned experts including Drs. Sandhaus, Stocks, Campos, and a live AATD patient during this dynamic evidence-based symposium. We’ll discuss several AATD patient types, such as high-risk genotype and low FEV1 as well as diagnostic considerations and therapeutic interventions, including augmentation therapy. In addition, you can submit your challenging AATD clinical cases and get expert opinions for management.

Speakers: Robert A. Sandhaus, MD, PhD, FCCP, professor of medicine, division of pulmonary, critical care and sleep medicine director, Alpha-1 program at the National Jewish Medical and Research Center; Michael A. Campos, MD, associate professor of medicine, division of pulmonary, allergy, critical care at the University of Miami School of Medicine; James M. Stocks, MD, professor of medicine at the University of Texas Health Science Center at Tyler

Company: RMEI Medical Education, supported by educational grants from Shire – part of Takeda, Grifols, and CLS Behring

6:30-9:30 p.m.
Paving the Way in Fibrotic Lung Disease: Expanding Applications for Existing Therapies
Sheraton Dallas Hotel, Lone Star Ballroom A2-A4

Expert faculty will discuss progressive fibrosing interstitial lung disease, providing guidance on its timely and accurate identification; they will also evaluate the expanding applications for current idiopathic pulmonary fibrosis therapies in other fibrotic lung diseases. Case presentations will provide scientific pearls for the integration of diagnostic and therapeutic algorithms into clinical practice.

Speakers: Amy L. Olson, MD, MSPH, associate professor in the department of medicine and medical director of the pulmonary physiology unit at National Jewish Health; Kevin R. Flaherty, MD, MS, professor of medicine in the division of pulmonary/critical care medicine and medical director at the Michigan Medicine ILD Clinic, University of Michigan; Steven D. Nathan, MD, medical director of the advanced lung disease and transplant program and professor of medicine at Inova Fairfax Hospital and Virginia Commonwealth University, Inova Fairfax Campus

Company: Vindico Medical Education, supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

6:30-9:30 p.m.
The Allergic Asthma Challenge
Hyatt Regency Dallas, Reunion Ballroom GH

Test your knowledge of allergic asthma! Drs. William J. Calhoun and Rey Panettieri will host a live educational event using a game show format — “The Allergic Asthma Challenge” — where dinner attendees have the opportunity to participate. The highest scoring participants from the first round will move on to compete on the main stage in the final round. Questions will focus on the following topics: asthma phenotypes
The Current State of Idiopathic Pulmonary Fibrosis

An Industry-Organized Symposium at the ATS 2019 International Conference

This symposium will enlist two expert pulmonologists presenting information on idiopathic pulmonary fibrosis (IPF). Current knowledge regarding IPF, including the updated 2018 ATS/ERS/JRS/ALAT diagnostic guidelines, as well as recommendations for use of multidisciplinary discussions in patient diagnosis, will be reviewed.

May 21, 2019
6:30 PM
Dinner/Symposium
Fairmont Dallas
Regency Ballroom

This presentation is sponsored by and made on behalf of Boehringer Ingelheim Pharmaceuticals, Inc. Presentation content has been reviewed for consistency with FDA guidelines and is not approved for continuing medical education credit. Speakers receive fair market value compensation for this presentation. Aspects of this program may be reportable under the Physicians Payment Sunshine Act. Pursuant to the PhRMA (Pharmaceutical Research and Manufacturers of America) Code on Interactions with Healthcare Professionals, attendance at this promotional program is limited to healthcare professionals, attendance by healthcare professionals’ spouses or guests is not permitted.
and endotypes, biomarkers in asthma, asthma-related comorbidities, and the role of IgE in allergic asthma. The program will conclude with a Q&A session with our two hosts.

**Speakers:** William J. Calhoun, MD, professor of medicine, vice chair for research, department of internal medicine at the University of Texas Medical Branch in Galveston, Texas; Reynold A. Panettieri Jr., MD, professor of medicine at the Robert Wood Johnson Medical School, Rutgers Institute for Translational Medicine in New Brunswick, New Jersey

**Company:** Genentech, A Member of the Roche Group, and Novartis Pharmaceuticals Corporation

---

**6:30-9:30 p.m.**

**The Changing Landscape of Nontuberculous Mycobacterial Lung Disease (NTM-LD): A 3D View of Pathogenesis, Diagnosis, and Management**

**Hyatt Regency Dallas, Landmark Ballroom C**

This engaging 3D satellite symposium offers a unique learning opportunity investigating NTM-LD. Worldwide prevalence has been increasing, with pervasive impacts exhibited among chronic and structural lung disease, aging, and immunocompromised populations. Through evidence-based didactics, case-based learning, and 3D animation, complexities of diagnosis and management will be explored for m. avium complex (MAC) and m. abscessus with the aim to: review microbiology, pathogenesis, and environmental aspects of NTM; summarize recent data on NTM epidemiology and risk factors; describe treatment goal personalization methodologies; assess drug-related adverse event prevention strategies; evaluate established and emerging therapy clinical data.

**Speakers:** Charles L. Daley, MD, chief of the division of mycobacterial and respiratory infections, professor of medicine at the National Jewish Health; Kevin Winthrop, MD, MPH, professor of public health, infectious disease and ophthalmology at Oregon Health & Science University

**Company:** Insmed Incorporated

---

**6:30-9:30 p.m.**

**The Current State of Idiopathic Pulmonary Fibrosis**

**Fairmont Dallas, Regency Ballroom**

This symposium will enlist two expert pulmonologists presenting information on idiopathic pulmonary fibrosis (IPF). Current knowledge regarding IPF, including the updated 2018 ATS/ERS/JRS/ALAT diagnostic guidelines, as well as recommendations for use of multidisciplinary discussions in patient diagnosis, will be reviewed.

**Speakers:** Justin Oldham, MD, MS, director of the interstitial lung disease program, assistant professor at the University of California, Davis; Robert Sussman, MD, attending in the department of medicine at Morristown Medical Center, Overlook Medical Center

**Company:** Boehringer Ingelheim Pharmaceuticals, Inc.

---

**6:30-9:30 p.m.**

**U.S. Presidents With Severe Asthma: Endotypes and Precision Medicine**

**Fairmont Dallas, International Ballroom**

This activity will delve into the lives of U.S. presidents with asthma, to draw a contrast between treatment approaches of the past and current and emerging therapies that target specific disease mechanisms. We’ll summarize mechanisms of action as well as key efficacy and safety data for cytokine antagonists being used or investigated for severe asthma treatment. The information learned will then be applied, using case scenarios, in selecting personalized treatments based on asthma phenotypes and endotypes.

**Speakers:** Tara Carr, MD, associate professor of medicine, associate professor of otolaryngology, director of the Adult Allergy Program, director of the Allergy & Immunobiology Fellowship Program, The University of Arizona Health Sciences; Nicola Hanania, MD, associate professor of medicine-pulmonary, director of the Airways Clinical Research Center, director of the asthma and COPD clinic at Baylor College of Medicine; Linda Rogers, MD, associate professor of medicine at the Icahn School of Medicine at Mount Sinai

**Company:** The France Foundation, supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals

**Register:** pilotforpulmonary.org/asthma19
Kay Bailey Hutchison Convention Center Dallas
Guru Bar 2
12:00 PM – 12:20 PM

FACULTY PRESENTER:
Cedric “Jamie” Rutland, MD
Assistant Clinical Professor of Internal Medicine
University of California Riverside School of Medicine

Fairmont Dallas
International Ballroom
6:30 PM – 9:30 PM

FACULTY PRESENTERS:
Geoff Chupp, MD, FACP
Professor of Medicine
Yale School of Medicine

Laren D. Tan, MD, FCCP
Assistant Professor
Loma Linda University Medical Center

DINNER WILL BE SERVED; SEATING IS LIMITED

Visit Booth #4515

A Non-CME educational program and Guru bar presentation sponsored by Sanofi Genzyme and Regeneron, and is open to all ATS 2019 International Conference attendees.

We are unable to provide meals in connection with this event to physicians employed by the federal government or licensed to practice in MA, MN, VT or NJ. Guests and spouses may not attend unless they would qualify as an appropriate attendee on their own.